<DOC>
	<DOCNO>NCT00952263</DOCNO>
	<brief_summary>This phase I , open-label , dose escalation study evaluate safety MBL-HCV1 healthy adult volunteer . Eligible volunteer admit phase 1 unit study infusion . A single dose human monoclonal antibody administer . The study duration 56 day . During time , safety assess via physical examination , laboratory testing , concomitant medication usage review treatment emergent adverse event occur . Pharmacokinetics derive analysis blood sample obtain 56 day study .</brief_summary>
	<brief_title>Study Healthy Volunteers Evaluate Human Monoclonal Antibody Against Hepatitis C</brief_title>
	<detailed_description>This phase I , open-label , dose escalation study healthy adult volunteer . Eligible volunteer admit phase I unit study infusion discharge collection 24 hour post infusion sample . Thirty subject anticipate enrolled . There five cohort 6 subject . A single dose human monoclonal antibody MBL-HCV1 administer Day 0 subject follow 56 day . Dose escalation next cohort occur review safety data principal investigator , sponsor independent safety monitor day 10 subject cohort . Assessment safety determine vital sign measurement , physical examination , hematology , chemistry urinalysis laboratory testing , electrocardiograms , use concomitant medication review treatment-emergent adverse event occur . Subjects evaluate study visit day 0 , 1 , 2 , 3 , 7 , 14+/-1 , 28+/-3 56+/-7 . Blood sample urinalysis safety analysis draw screen day 0 , 1 , 3 , 7 28+/-3 . Blood sample Pharmacokinetic analysis drawn day 0 , 1 , 2 , 3 , 7 , 14+/-1 , 28+/-3 56+/-7 . Blood sample human anti-human antibody detection drawn day 0 , 14+/-1 56+/-7 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Study subject must read , understood provide write informed consent HIPAA authorization nature study fully explain . 2 . Be &gt; equal 18 year age &lt; equal 55 year age . 3 . Be general good health without history condition list exclusion criterion . 4 . No use tobacco product least 6 month . 5 . A woman must agree become pregnant time study enrollment least 3 month completion monoclonal antibody infusion . If woman sexually active history hysterectomy tubal ligation , must agree use hormonal barrier birth control spermicidal gel . 6 . Sexually active male subject must use barrier method contraception course study . 7 . Screening laboratory value must meet following criterion : WBC ( &gt; 3,900 &lt; 11,000/mm^3 ) Platelets ( &gt; 100,000/mm^3 ) Hemoglobin ( &gt; 10.5 gm/dl ) Creatinine ( &lt; 1.1 x ULN ) BUN ( &lt; 1.25 x ULN ) AST ( &lt; 1.1 x ULN ) ALT ( &lt; 1.1 x ULN ) Alkaline Phosphatase ( &lt; 1.1 x ULN ) Bilirubin ( &lt; 1.1 x ULN ) Glucosenonfasting ( &gt; /=60 mg/dl &lt; /=115 mg/dl ) 1 . Previous receipt humanize human monoclonal antibody whether licensed investigational . 2 . Weight &gt; 90 kg 3 . History follow illness condition : Cancer Heart Disease Diabetes mellitus Respiratory condition ( asthma require daily medication ) Autoimmune disorder Blood dyscrasia Psychiatric disorder precludes compliance protocol Hepatitis 4 . Any chronic condition require daily prescription overthecounter medicine except vitamin birth control product . 5 . Drug alcohol abuse within previous 12 month positive screen within 24 hour monoclonal antibody administration . 6 . History previous severe allergic reaction generalize urticaria ; angioedema anaphylaxis . 7 . Physical finding examination consider clinically significant murmur ( functional ) , hepatosplenomegaly , lymphadenopathy focal neurological deficit . 8 . Systolic blood pressure &gt; 140 &lt; 90 and/or diastolic blood pressure &gt; 90 two separate reading . 9 . Urinalysis positive &gt; trace protein , &gt; 5 rbc/hpf &gt; 5 wbc/hpf 10 . Positive serology HIV antibody , HCV antibody Hepatitis B surface antigen . 11 . Positive urine pregnancy test screening within 24 hour monoclonal antibody administration , unwillingness undergo pregnancy test . 12 . Breastfeeding . 13 . Receipt license vaccine investigational study agent within previous 30 day . 14 . Any condition opinion investigator would jeopardize safety right volunteer participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Phase I</keyword>
	<keyword>Infusion</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>MBL-HCV1</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Safety Assessment</keyword>
</DOC>